Second quarter results
Executive Summary
Detrol, the anti-glaucoma agent Xalatan ($68 mil. in sales, up 92% in local currency), the low-molecular heparin Fragmin ($48 mil., up 21%), and the oncologic Camptosar ($44 mil., up 16%) helped the company post a 7% increase in sales (excluding currency) to $1.65 bil. for the quarter. Earnings grew 13% to $187 mil., excluding a $41 mil. after-tax charge related to the settlement of retail pharmacy prescription pricing litigation